Table 1.

Potential savings (in Euro) from increased generic substitution in Poland, 2004

Active substance	Public expenditure on originator medicines	Savings from generic substitution*
Simvastatin	10 088 853	623 500 (6%)
Gliclazide	8 145 560	304 841 (4%)
Azithromycin	7 756 479	84 458 (1%)
Amoxicillin	6 232 929	811 800 (13%)
Donepezil	6 028 764	3 012 783 (50%)
Budesonide	6 317 025	3 855 495 (61%)
Atorvastatin	4 990 985	2 000 705 (40%)
Cetirizine	4 646 962	484 645 (10%)
Total	54 207 557	11 178 228 (21%)

*Savings from generic substitution are expressed in absolute terms and as a percentage of public expenditure on originator medicines.